Medartis Holding AG (XSWX:MED) ROCE %: 4.61% (As of Dec. 2025)


XSWX:MED Medartis Holding AG XSWX:MED
76 GF Score
Price CHF72.00
GF Value CHF105.61
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Medartis Holding AG ROCE %?

Medartis Holding AG XSWX:MED -0.55% 76 ROCE % is 4.61% as of Dec. 2025. GuruFocus rates XSWX:MED with a GF Score™ of 76/100 and a GF Value™ of CHF105.61 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medartis Holding AG's annualized ROCE % for the quarter that ended in Dec. 2025 was 4.61%.

Medartis Holding AG  (XSWX:MED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medartis Holding AG ROCE % Related Terms

Medartis Holding AG ROCE % Historical Data

* Premium members only.

The historical data trend for Medartis Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medartis Holding AG ROCE % Chart

Medartis Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.47 -2.32 0.89 2.21 4.60

Medartis Holding AG Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 3.10 1.17 4.87 4.61
XSWX:MED
76GF Score
Medartis Holding AG XSWX:MED
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medartis Holding AG ROCE % Calculation

Medartis Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=20.265/( ( (459.961 - 51.018) + (559.922 - 88.173) )/ 2 )
=20.265/( (408.943+471.749)/ 2 )
=20.265/440.346
=4.60 %

Medartis Holding AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=20.442/( ( (465.703 - 49.893) + (559.922 - 88.173) )/ 2 )
=20.442/( ( 415.81 + 471.749 )/ 2 )
=20.442/443.7795
=4.61 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.61% mean?
Medartis Holding AG (XSWX:MED) has a ROCE % of 4.61% as of Dec. 2025.
Is Medartis Holding AG's ROCE % too high?
Medartis Holding AG's current ROCE % is 4.61%. The Medical Devices & Instruments industry median ROCE % is 2.23. Medartis Holding AG's value of 4.61% is 106.7% above this industry median. Overall, Medartis Holding AG has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's ROCE % compare to ABT and SYK?
Medartis Holding AG's ROCE % of 4.61% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Medartis Holding AG's value of 4.61% is 106.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current ROCE % of 4.61% is 106.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current ROCE % is 4.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF105.61, compared to a current price of CHF72.00 — trading 31.8% below its estimated fair value. The current ROCE % is 4.61% and 106.7% above the Medical Devices & Instruments industry median of 2.23. Medartis Holding AG's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current ROCE % is 4.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?

Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued. The current stock price of CHF72.00 is trading 31.8% below its estimated GF Value™ of CHF105.61. GuruFocus considers Medartis Holding AG to be Significantly Undervalued.

Key valuation signals for XSWX:MED:

  • ROCE %: 4.61%
  • GF Value™: CHF105.61 vs. price of CHF72.00 (31.8% below fair value)
  • GF Score™: 76/100 with 5 warning signs
  • Industry Position: 106.7% above the Medical Devices & Instruments median

No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medartis Holding AG Business Description

Other Exchanges MEDz:UK1RU:Germany
Address Hochbergerstrasse 60E, Basel, CHE, 4057
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
76GF Score

Get the complete analysis for XSWX:MED

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.00
Price
CHF105.61
GF Value